Cash from Operations (Quarterly) Chart

Historical Cash from Operations (Quarterly) Data

View and export this data back to 2017. Start Trial.
Date Value
September 30, 2026 -23.34M
June 30, 2026 -31.59M
March 31, 2026 -45.72M
December 31, 2025 -9.979M
September 30, 2025 -31.91M
June 30, 2025 12.23M
March 31, 2025 -3.407M
December 31, 2024 -39.45M
September 30, 2024 -6.053M
June 30, 2024 -24.55M
March 31, 2024 -37.68M
December 31, 2023 15.58M
September 30, 2023 -42.91M
June 30, 2023 -6.716M
March 31, 2023 -83.19M
December 31, 2022 318.20M
September 30, 2022 -70.21M
June 30, 2022 -54.38M
March 31, 2022 -55.41M
December 31, 2021 -50.09M
Date Value
September 30, 2021 -48.74M
June 30, 2021 -51.77M
March 31, 2021 -40.80M
December 31, 2020 -50.95M
September 30, 2020 -18.73M
June 30, 2020 -48.68M
March 31, 2020 -37.49M
December 31, 2019 -36.44M
September 30, 2019 -11.33M
June 30, 2019 -13.21M
March 31, 2019 -21.30M
December 31, 2018 49.26M
September 30, 2018 -12.55M
June 30, 2018 4.592M
March 31, 2018 -17.57M
December 31, 2017 40.76M
September 30, 2017 -14.10M
June 30, 2017 -13.74M
March 31, 2017 -12.70M

Cash From Operations Definition

Represents the net cash flow from the company's business operations.

Read full definition.

Cash from Operations (Quarterly) Range, Past 5 Years

View Cash from Operations (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Operations (Quarterly) Benchmarks

View Cash from Operations (Quarterly) Benchmarks
Start Trial
AbbVie, Inc. 7.606B
Faeth Therapeutics, Inc. -13.00M
ACADIA Pharmaceuticals, Inc. 11.50M
Alnylam Pharmaceuticals, Inc. 340.98M
Anika Therapeutics, Inc. 8.377M